Clinical Trial Update: Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating ixazomib with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Pomalidomide (Pomalidomide)
• ixazomib (ixazomib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-16